• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Development and validation of a multivariate risk model for distant metastasis of advanced nasopharyngeal carcinoma].[晚期鼻咽癌远处转移多因素风险模型的建立与验证]
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Dec 30;38(12):1459-1464. doi: 10.12122/j.issn.1673-4254.2018.12.10.
2
Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.诱导化疗后循环 EBV DNA 水平可预测晚期鼻咽癌的预后。
Eur J Cancer. 2021 Jul;151:63-71. doi: 10.1016/j.ejca.2021.03.052. Epub 2021 May 5.
3
Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.整合模型纳入转移性区域颈淋巴结体积和治疗前血清爱泼斯坦-巴尔病毒DNA拷贝数在预测N1期鼻咽癌患者远处转移中的预后价值
Chin J Cancer. 2017 Dec 29;36(1):98. doi: 10.1186/s40880-017-0264-x.
4
A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.一种新的评分模型,用于预测 II-IVa 期鼻咽癌同期放化疗中附加诱导化疗的获益。
Oral Oncol. 2018 Nov;86:258-265. doi: 10.1016/j.oraloncology.2018.10.007. Epub 2018 Oct 10.
5
Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.血清 Epstein-Barr 病毒抗体的预后价值及其与局部晚期鼻咽癌 TNM 分期的相关性。
Cancer Res Treat. 2021 Oct;53(4):991-1003. doi: 10.4143/crt.2020.1298. Epub 2021 Jan 13.
6
Plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in Nasopharyngeal Carcinoma.基于血浆蛋白的生物标志物可预测鼻咽癌的远处转移和诱导化疗获益。
Theranostics. 2020 Aug 1;10(21):9767-9778. doi: 10.7150/thno.47882. eCollection 2020.
7
Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.新辅助化疗或辅助化疗联合同期放化疗与单纯同期放化疗治疗鼻咽癌的比较:基于 EBV DNA 的研究。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):703-710. doi: 10.6004/jnccn.2018.7270.
8
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.基于基因表达signature 预测局部晚期鼻咽癌远处转移的建立和验证:一项回顾性、多中心队列研究。
Lancet Oncol. 2018 Mar;19(3):382-393. doi: 10.1016/S1470-2045(18)30080-9. Epub 2018 Feb 7.
9
Selectively recommend F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas.建议在鼻咽癌高发地区对初诊鼻咽癌患者进行 F-FDG PET/CT 检查。
Radiat Oncol. 2021 Nov 27;16(1):229. doi: 10.1186/s13014-021-01954-8.
10
Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.在调强放射治疗时代,基于顺铂的同步放化疗治疗局部和区域晚期鼻咽癌时血浆EB病毒DNA的预后价值
Medicine (Baltimore). 2016 Feb;95(5):e2642. doi: 10.1097/MD.0000000000002642.

引用本文的文献

1
The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.同期放化疗联合多西他赛加顺铂或多西他赛或顺铂和螺旋断层放疗治疗局部晚期鼻咽癌的急性毒性和疗效:一项随机单中心 II 期试验。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221109974. doi: 10.1177/15330338221109974.

本文引用的文献

1
Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.基于大数据智能平台分析优化局部晚期鼻咽癌患者的诱导化疗方案。
Oral Oncol. 2018 Apr;79:40-46. doi: 10.1016/j.oraloncology.2018.02.011. Epub 2018 Feb 16.
2
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.基于基因表达signature 预测局部晚期鼻咽癌远处转移的建立和验证:一项回顾性、多中心队列研究。
Lancet Oncol. 2018 Mar;19(3):382-393. doi: 10.1016/S1470-2045(18)30080-9. Epub 2018 Feb 7.
3
HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma.HOPX 高甲基化通过激活鼻咽癌中的 SNAIL 转录促进转移。
Nat Commun. 2017 Feb 1;8:14053. doi: 10.1038/ncomms14053.
4
Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment.预测非转移性鼻咽癌患者治愈性治疗后生存情况的列线图的开发与验证
Chin J Cancer. 2016 Nov 25;35(1):98. doi: 10.1186/s40880-016-0160-9.
5
An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study.一种基于炎症生物标志物的列线图预测鼻咽癌患者预后:一项前瞻性研究分析
Cancer Med. 2017 Jan;6(1):310-319. doi: 10.1002/cam4.947. Epub 2016 Nov 10.
6
Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application.用于识别超重和肥胖血清生物标志物的最小绝对收缩和选择算子类型方法:模拟与应用
BMC Med Res Methodol. 2016 Nov 14;16(1):154. doi: 10.1186/s12874-016-0254-8.
7
Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy.预测鼻咽癌患者根治性放疗后生存的列线图的开发与外部验证
Sci Rep. 2015 Oct 26;5:15638. doi: 10.1038/srep15638.
8
Nasopharyngeal carcinoma.鼻咽癌
Surg Oncol Clin N Am. 2015 Jul;24(3):547-61. doi: 10.1016/j.soc.2015.03.008. Epub 2015 Apr 11.
9
Involvement of both cervical lymph nodes and retropharyngeal lymph nodes has prognostic value for N1 patients with nasopharyngeal carcinoma.颈淋巴结和咽后淋巴结均受累对鼻咽癌N1期患者具有预后价值。
Radiat Oncol. 2014 Jan 6;9:7. doi: 10.1186/1748-717X-9-7.
10
Prognostic model for distant metastasis in locally advanced nasopharyngeal carcinoma after concurrent chemoradiotherapy.同步放化疗后局部晚期鼻咽癌远处转移的预后模型
Head Neck. 2015 Feb;37(2):209-14. doi: 10.1002/hed.23583. Epub 2014 Mar 25.

[晚期鼻咽癌远处转移多因素风险模型的建立与验证]

[Development and validation of a multivariate risk model for distant metastasis of advanced nasopharyngeal carcinoma].

作者信息

Zhang Lu, Luo Xiaoning, Mo Xiaokai, Huang Wenhui, Liang Changhong, Zhang Shuixing

机构信息

Graduate College, Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.

Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510282, China.

出版信息

Nan Fang Yi Ke Da Xue Xue Bao. 2018 Dec 30;38(12):1459-1464. doi: 10.12122/j.issn.1673-4254.2018.12.10.

DOI:10.12122/j.issn.1673-4254.2018.12.10
PMID:30613014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6744206/
Abstract

OBJECTIVE

To develop a model based on the clinical variables for evaluating the risk of distant metastasis in patients with advanced nasopharyngeal carcinoma (NPC).

METHODS

From September,2007 to June,2015,a total of 238 consecutive patients with biopsy-proven NPC in stage Ⅲ-Ⅳ(M0) based on the AJCC TNM staging manual were enrolled in this study,including 106 male and 34 female patients with a median age of 45 years (range 18-68 years).In this cohort,126 patients received concurrent chemoradiotherapy,and 24 received chemotherapy and radiotherapy,and 40 had induction chemotherapy.We used the least absolute shrinkage and selection operator (LASSO) method to select the most significant features for establishing the model for assessing the risks of distant metastasis.

RESULTS

Among the 18 clinical variables tested,5 were significantly associated with distant metastasis in advanced NPC,including plasma Epstein-Barr virus (EBV) DNA,neutrophil/lymphocytes (NLR),VCA-IgA,concurrent chemoradiotherapy,and induction chemotherapy.Based on these 5 clinical variables,we established the following model:risk score=1.73×EBV DNA+0.54×NLR+0.38×VCA-IgA-0.95×concurrent chemoradiotherapy-2.37×induction chemotherapy+0.51.The cutoff point of this model was-0.62,which classified the patients into high-risk and low-risk groups for distant metastasis.This model showed a good performance in predicting distant metastasis in patients with advanced NPC (<0.01).

CONCLUSIONS

The model we established herein can be used for evaluating the risks of distant metastasis in patients with advanced NPC and provides assistance in the clinical decision-making on individualized treatment strategy.

摘要

目的

建立一种基于临床变量的模型,用于评估晚期鼻咽癌(NPC)患者远处转移的风险。

方法

2007年9月至2015年6月,本研究共纳入238例经活检证实为Ⅲ-Ⅳ期(M0)的NPC患者,依据美国癌症联合委员会(AJCC)TNM分期手册,其中男性106例,女性34例,中位年龄45岁(范围18-68岁)。在该队列中,126例患者接受同步放化疗,24例接受化疗和放疗,40例接受诱导化疗。我们使用最小绝对收缩和选择算子(LASSO)方法选择最显著特征,以建立评估远处转移风险的模型。

结果

在测试的18个临床变量中,5个与晚期NPC的远处转移显著相关,包括血浆EB病毒(EBV)DNA、中性粒细胞/淋巴细胞(NLR)、VCA-IgA、同步放化疗和诱导化疗。基于这5个临床变量,我们建立了以下模型:风险评分=1.73×EBV DNA+0.54×NLR+0.38×VCA-IgA-0.95×同步放化疗-2.37×诱导化疗+0.51。该模型的截断点为-0.62,据此将患者分为远处转移的高风险和低风险组。该模型在预测晚期NPC患者的远处转移方面表现良好(<0.01)。

结论

我们在此建立得模型可用于评估晚期NPC患者远处转移的风险,并为个体化治疗策略的临床决策提供帮助。